Polyamine Inhibitor Therapy Selection Using Molecular Markers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments for carcinomas, such as colorectal cancer, face challenges in identifying suitable patients for preventative or curative regimes due to the lack of genetic features that determine individual suitability, leading to modest efficacy and side effects from existing polyamine-inhibitory therapies like DFMO and sulindac.
Innovation Solution
The method involves determining the expression levels of let-7 non-coding RNA, HMGA2 protein, or LIN28 protein in patients to tailor the administration of ornithine decarboxylase (ODC) inhibitors like DFMO and non-steroidal anti-inflammatory drugs (NSAIDs), with genotype-specific adjustments at the ODC1 gene promoter position +316 to optimize treatment efficacy and minimize side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If polyamine-inhibitory therapy (DFMO and sulindac) is administered to all patients, then cancer prevention efficacy is improved, but side effects (ototoxicity and cardiovascular events) increase
Solution Approach 1:
The patent applies local quality by identifying specific genetic subgroups (ODC1 +316 GG genotype, low let-7 expression, high HMGA2 expression) that will benefit from polyamine-inhibitory therapy. Instead of uniform treatment, the therapy is targeted to patients with specific molecular characteristics, thereby improving efficacy while reducing unnecessary side effects in non-responsive patients.
Solution Approach 2:
The patent utilizes parameter changes by measuring molecular markers (let-7 expression, HMGA2 expression, LIN28 expression, ODC1 genotype) to identify patient subgroups. These parameter measurements enable differentiation between patients who will respond to therapy and those who will not, allowing personalized treatment decisions that balance efficacy and side effect prevention.
2Ease of operation
If polyamine-inhibitory therapy is administered without genetic screening, then treatment accessibility is improved, but treatment efficacy decreases due to lack of patient selection
Solution Approach 1:
The patent applies preliminary action by performing genetic screening and molecular marker assessment before administering polyamine-inhibitory therapy. This pre-treatment evaluation identifies patients who are most likely to benefit from the therapy, ensuring that treatment is both accessible and effective by selecting the right patients beforehand.
3Reliability
If molecular marker testing (let-7, HMGA2, LIN28) is performed to personalize treatment, then treatment efficacy is improved, but diagnostic complexity increases
Solution Approach 1:
The patent applies universality by developing a comprehensive diagnostic system that evaluates multiple molecular markers (let-7, HMGA2, LIN28, ODC1 genotype) within a unified framework. This multi-functional assessment approach integrates various tests into a single personalized treatment decision process, managing complexity through systematic integration rather than isolated evaluations.
Data Source
AI summary
The present invention relates to therapeutic methods and medical uses comprising the identification and use of cancer marker surrogates for increased polyamine expression. These markers may be used to identify patients who may be treated for diseases and disorders that are susceptible to polyamine synthesis inhibitors, and they can also be used to monitor therapeutic responses when such agents are used.